2021
The Appraisal of Body Content (ABC) trial: Increased male or female adiposity does not significantly impact in vitro fertilization laboratory or clinical outcomes
Kim J, Patounakis G, Juneau C, Morin S, Neal S, Bergh P, Seli E, Scott R. The Appraisal of Body Content (ABC) trial: Increased male or female adiposity does not significantly impact in vitro fertilization laboratory or clinical outcomes. Fertility And Sterility 2021, 116: 444-452. PMID: 33581854, DOI: 10.1016/j.fertnstert.2020.12.037.Peer-Reviewed Original ResearchConceptsBody mass indexBioelectric impedance analysisLive birth rateLow birth weightClinical outcomesMiscarriage rateBlastocyst formation rateEuploidy rateImplantation rateBirth weightLow birth weight/Low birth weight infantsNormal weight patientsBirth weight infantsProspective cohort studyImpact of obesityFertilization laboratoryBirth rateFertilization rateBF categoriesWeight patientsMaternal obesityWeight infantsCohort studyObese women
2019
Diminished ovarian reserve versus ovarian aging: overlaps and differences.
Ata B, Seyhan A, Seli E. Diminished ovarian reserve versus ovarian aging: overlaps and differences. Current Opinion In Obstetrics & Gynecology 2019, 31: 139-147. PMID: 30870184, DOI: 10.1097/gco.0000000000000536.Peer-Reviewed Original ResearchConceptsNormal ovarian reserveOvarian reservePregnancy lossOocyte qualityReproductive technology cyclesAge-matched womenDiminished ovarian reserveLow ovarian reserveFetal chromosomal abnormalitiesQuantitative declineFecundity of womenOvarian stimulationNatural conceptionOvarian agingPoor responseART treatmentAged womenYoung womenChromosomal abnormalitiesAvailable evidenceDecreased numberQualitative declineOocyte poolWomenBlastocyst development
2002
Should patients with polycystic ovarian syndrome be treated with metformin?
Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Human Reproduction 2002, 17: 2230-2236. PMID: 12202407, DOI: 10.1093/humrep/17.9.2230.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeTreatment of PCOSInsulin-lowering agentsOvarian syndromePathogenesis of PCOSType 2 diabetes mellitusPromising therapeutic profileEarly spontaneous miscarriageOral antihyperglycaemic agentsInsulin-sensitizing drugsType 2 diabetesRisk of developmentImportant aetiologic factorPlasminogen activator inhibitorSerum lipidsDiabetes mellitusCardioprotective effectsAetiologic factorsAntihyperglycaemic agentsInsulin resistanceSpontaneous miscarriageMetforminTherapeutic profileActivator inhibitorTreatment